Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653271 · ClinicalTrials.gov registry record · Phase 1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
A Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, sponsored by Acepodia Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 13
- Study locations
NCT05653271 is a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma that is actively recruiting participants, run by Acepodia Biotech. The registered enrollment target is 42 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (72% lower). The trial reports 13 study locations across 6 states.
The verdict
NCT05653271, a Phase 1 study of Non-Hodgkin Lymphoma and Follicular Lymphoma, is actively recruiting participants, sponsored by Acepodia Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 13
- Study locations
Study Summary
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG ACE1831
Study Locations (13)
Other
- Queen Mary Hospital - Hong Kong
- Kaohsiung Chang-Gung Memorial Hospital - Kaohsiung City
- Ministry of Health and Welfare Shuang-Ho Hospital - New Taipei City
- Tamsui MacKay Memorial Hospital - New Taipei City
- Taichung Veterans General Hospital - Taichung
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
- Linkou Chang-Gung Memorial Hospital - Taoyuan
Florida
- AdventHealth Orlando - Orlando
Georgia
- Emory University - Atlanta
Indiana
- Indiana University Simon Comprehensive Cancer Center - Indianapolis
Kentucky
- Norton Cancer Institute - Louisville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-01-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05653271
The ClinicalTrials.gov registry entry for NCT05653271 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (72% lower). The listed sponsor is Acepodia Biotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT05653271 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05653271 about?
NCT05653271 is a clinical study titled "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies". ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety an...
What is the current status of trial NCT05653271?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-01-21. Estimated completion is 2027-09.
What conditions does trial NCT05653271 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, High Grade B-Cell Lymphoma.
What interventions are being tested in trial NCT05653271?
The interventions under investigation include: Obinutuzumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), ACE1831 (DRUG).
Who is sponsoring clinical trial NCT05653271?
This trial is sponsored by Acepodia Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653271 being conducted?
This trial has 13 study locations across Florida, Georgia, Indiana, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.